Table 3 Number of adverse events reported in ≥ 5% of subjects by treatment group
AE description | Synvisc-One n = 32 | Hydros n = 32 | Hydros-TA n = 34 |
|---|---|---|---|
Any TEAE, n (%) | 23 (72) | 24 (75) | 21 (62) |
Arthralgia, n (%) | 8 (25) | 11 (34) | 7 (21) |
Joint Swelling, n (%) | 2 (6) | 3 (9) | 2 (6) |
Joint Stiffness, n (%) | 2 (6) | 3 (9) | 0 |
Back Pain, n (%) | 3 (9) | 1 (3) | 1 (3) |
Muscle Spasms, n (%) | 1 (3) | 0 | 3 (9) |
Arthritis, n (%) | 0 | 2 (6) | 0 |
Headache, n (%) | 8 (25) | 6 (19) | 4 (12) |
Nasopharyngitis, n (%) | 3 (9) | 1 (3) | 1 (3) |
Nausea, n (%) | 1 (3) | 2 (6) | 1 (3) |
Meniscus Lesion, n (%) | 1 (3) | 0 | 2 (6) |
Tendon Pain, n (%) | 2 (6) | 0 | 0 |